An expanding HealthTech ecosystem - Cluster i-Care

Special magazine Medica 2017

#3

An expanding HealthTech ecosystem

Implants

Connected health Medical imaging Medical plastics Minimally invasive technologies

Medical textiles

© iStock photos

Biomaterials

Contents 2/E ditorial by Michel Plantevin 3 / Auvergne-Rhône-Alpes An area for new opportunities

HEALTH TECHNOLOGY AUVERGNE-RHÔNE-ALPES CLUSTER

4 / LyonBiopôle The gateway to healthcare innovation

To mark the Medica 2017 exhibition,

Michel PLANTEVIN,

6 / Edap TMS Therapeutic ultrasound

President of i-Care Cluster Health Technology Auvergne-Rhône-Alpes, answers our questions.

7 / Texinov Medical textiles 9 / BioparHom Connected health 10 / NeoMedLight Medical devices 11 / Rhizom Connected health 12 / Setmi Medical devices 13 / ADERLY Economic Development Agency 14 / AEPI & Grenoble Alpes Métropole Economic Development Agency 15 / Medi’Nov Connection 2018

Michel Plantevin, you are taking over the presidency of i-Care Cluster from Emmanuel Blanc: who are you and what is your vision for the cluster? Michel Plantevin - I have been involved in the cluster for three years as a member and as an officer on behalf of the company I run, Solware Life, a software company in the healthcare sector. During that time I have been able to evaluate the benefits of contributing to the development of the regional health technology ecosystem. The work of my predecessor and his teams has borne fruit: we now have 120 members and i-Care has reinforced its position in the regional health ecosystem in recent years. This momentum must not weaken, because digital is an essential subject in all activity sectors, including health technology. As a player in the young digital economy and an IT publisher with an international presence, I fully intend to contribute my experience and bring a new eye to the subject: the i-Care Cluster must be at the heart of the digital transformation of health organisations and practices. From the region to Europe and beyond… this is your priority goal, but what levers can you use to achieve it? MP - Our region is France’s second biggest economy, the fourth in medical and health technology and the eighth in Europe… not to mention that 25% of France’s medical equipment industry is based in Auvergne-Rhône-Alpes. The first lever we can use thus has considerable legitimacy - the region’s economic importance. The second has equal weight, and consists of the excellence of our sector. Two strengths to boost our international reach - let’s activate them. As the former chair of Four Motors for Europe, created twenty years ago by the regions of Rhône-Alpes, Lombardy, Catalonia and Baden-Württemberg, the region organised a working mission to Scandinavia in September, where I represented the i-Care Cluster alongside representatives of life science clusters from the three other regions. The goal? To meet innovative players in the life sciences from northern Europe. This mission is an example of a powerful lever, shining a spotlight on all the skills of our region, presenting opportunities for partnerships and chances to create exchanges of intelligence and stimulate activity. Attentive to the operation of Danish and Swedish clusters, which are very innovative in terms of organisation, governance and added-value services for their members, i-Care has forged links to gradually create a kind of Europe-wide mesh that will be beneficial for all. Other levers, such as organising Techdays in the region and attending the Entretiens Jacques Cartier in Montreal (Canada) and the Medica exhibition in Düsseldorf (Germany), also help to consolidate the reputations of our companies in Europe and gain international visibility. The international Medica 2017 show: is this a high point for the i-Care Cluster?

This magazine is published by the i-Care Cluster Managing editor: Gérald Comtet Design & production: artenium, Laurent Annino, Camille Guy Copywriter: Hervé Heurteau 2 rue des Mûriers - Villa Créatis 69009 Lyon - France www.artenium.com

MP - It is one of the highlights of the year, because we organize attendance at the exhibition for the companies and partners concerned. But as I said, this international event is part of a global support strategy aiming to boost the activity of our companies. And to serve our members better and improve further, we must develop new added-value initiatives for our members, such as open innovation and experimentation through use (Living Lab), and evolve our methods of operation to give the cluster’s economic model a long-term future like the Scandinavian clusters have done. In the immediate future, the companies and start-ups exhibiting at the collective stand organised by the i-Care Cluster have a strong hand: I wish them all a great exhibition!

Michel Plantevin,

President of the i-Care Cluster

2

i-Care mag #3 / Health Technology in Auvergne-Rhône-Alpes

Auvergne-Rhône-Alpes an area for new opportunities

European

13 %

crossroads

1st French

of the French territory

industrial region

Moulins

ALLIER

Bourg-en -Bresse

HAUTE-SAVOIE AIN

RHÔNE

Clermont-Ferrand

Lyon

LOIRE

Chambery

PUY-DE-DÔME

SaintEtienne

CANTAL

€240bn GDP

Annecy

SAVOIE

ISÈRE

Grenoble

HAUTE-LOIRE

Le Puy-en-Velay Aurillac

ARDÈCHE

Valence

Privas DRÔME

7.8 M Research & development

residents

2.71% GDP

(2.69% GDP for North America)


3

Auvergne - R hône - Alpes Auvergne - R hône - Alpes Auvergne - R hône - Alpes

Au ve rgn e - R hô ne - Al pes

The gateway to healthcare innovation

BOOST your business in Europe BOOST your business BOOST + €708 M your business in Europe OFin PRIVATE MONEY RAISED Europe €708 M BY+LYONBIOPOLE MEMBERS + M MONEY RAISED OF€708 PRIVATE since 2013 OF PRIVATE MONEY RAISED BY LYONBIOPOLE MEMBERS BY LYONBIOPOLE MEMBERS since 2013 since 2013

INNOVATE in a dynamic ecosystem INNOVATE INNOVATE 213 R&D PROJECTS FUNDED in a dynamic ecosystem in a dynamic ecosystem since 2005

213€992 R&DM PROJECTS FUNDED of total investment 213 R&D PROJECTSsince FUNDED 2005 €406 M public funding since 2005 €992 M of total investment €992€406 M ofMtotal investment public funding €406 M public funding

200 MEMBERS MEMBERS > 200 4 WORLD CLASS LEADERS 200 MEMBERS > 180 INNOVATIVE COMPANIES

> 4 WORLD CLASS LEADERS > 16>RESEARCH &CLASS CLINICAL CENTERS > 4 WORLD LEADERS 180 INNOVATIVE COMPANIES > 180 INNOVATIVE COMPANIES > 16 RESEARCH & CLINICAL CENTERS > 16 RESEARCH & CLINICAL CENTERS GATHERED THROUGH 95 EVENTS PER YEAR, (CO)-ORGANIZED GATHERED THROUGHBY 95LYONBIOPOLE EVENTS PER YEAR, GATHERED THROUGH 95 LYONBIOPOLE EVENTS PER YEAR, (CO)-ORGANIZED BY (CO)-ORGANIZED BY LYONBIOPOLE

GO GLOBAL GLOBAL & GO access new markets GO GLOBAL & access newSUPPORTED markets 105 COMPANIES & access new markets 105 COMPANIES SUPPORTED IN 7 MISSIONS 105 COMPANIES IN 7 MISSIONS around the world in SUPPORTED 2016 IN 7 MISSIONS around the world in 2016 around the world in 2016

HOST your company your company in BSL2HOST & BSL3 laboratories HOST your company in BSL2&&GMP/GLP BSL3 laboratories facilities in BSL2 & BSL3 laboratories & GMP/GLP facilities 26 ORGANIZATIONS HOSTED & GMP/GLP facilities

26 ORGANIZATIONS HOSTED in 2016 26 ORGANIZATIONS HOSTED in 2016 in 2016

Lyonbiopole’s fo under s Lyon biopo l e’s fo u nd ers Lyon biopo l e’s fo u nd ers

ww ww ww . . l l yy oo nn bb ii oo pp w w w . l y o n b i o p 4


o o o

ll l

m ee .. cc oo m e . c o m

Discover Discover

2 COMPANIES 4 Start-ups

5



5

THERAPEUTIC ULTRASOUND

EDAP TMS has been innovating for 38 years in the field of non-invasive therapies, using therapeutic ultrasound to treat multiple pathologies, primarily in the field of urology. Interview with Emmanuel Blanc, Director of the EDAP TMS R&D team.

Interview with Emmanuel BLANC

Development Director - CTO T. +33(0)472 153 150 Cell. +33(0)620 822 421

Revenue: €35.6 B, 73% from exports

Contact:

6 subsidiaries (USA, Japan, South Korea, Malaysia, Italy, Germany) 2 offices in Dubai and Moscow

Maude PAVAGEAU

12%

16

[email protected] www.edap-tms.com www.hifu-prostate.com

12% of revenue devoted to R&D

16 R&D engineers

Communication Manager

You rely on local players to develop your activity: is this a key element of your success? Ever since its foundation, EDAP TMS has exploited the richness of the regional economic fabric and its expertise in the medical and healthcare field. By involving the best specialists in basic research (INSERM) and clinical research (CHU Édouard Herriot and Léon Bérard, the HCL) and working with the best-performing suppliers and manufacturers to develop its projects, EDAP TMS has made rapid progress. At the same time, our teams have contributed to the regional dynamic by getting involved with the region’s competitive clusters and skills hubs. The vitality of the local economic ecosystem is definitely one of the keys to our success. At the heart of your development is R&D: how does EDAP TMS contribute to the effectiveness of diagnoses and treatments, and ultimately to improving patient comfort? We involve our partners in the medical sector and innovative manufacturers in our product design process from the very beginning. We save valuable time by conducting the necessary research and clinical studies, the development of innovative technologies such as high-tech MRI imaging and the completion of the legal

6


180 patents registered (114 granted)

accreditation all at the same time. This is how we help improve patients’ treatment pathways in our field of therapeutic intervention, prostate cancer and urinary stones: better diagnostic performance, extremely precise treatment, reduced invasiveness, greater clinical effectiveness (low morbidity) – and thus improved patient comfort and better quality of life! You already export your equipment: what do you hope to gain from Medica 2017? We export a large proportion of our production throughout Europe and the world. Our HIFU equipment (Ablatherm® HIFU and Ablatherm® Fusion, an evolution of Ablatherm® HIFU incorporating the merging of diagnostic images) is exported to the USA. Focal One, the latest generation of HIFU device dedicated to focal therapy for prostate cancer, is currently undergoing FDA approval to be exported there soon as well. Medica is an opportunity to demonstrate our expertise, but beyond this purely technological aspect it is also a valuable opportunity to make new contacts. Distributors and basic research partners, designers and manufacturers of high-tech medical systems and components… all are able to contribute to our international development and will be welcome contacts.

MEDICAL TEXTILES

MDB Texinov specializes in the design, development and production of warp-knitting technical textiles. The R&D team - thanks to its expertise in polymers and textile engineering is developing solutions intended for wound care and implants. Starting with the yarn, through beaming, knitting, decontamination and heat-setting, MDB Texinov can complete all stages of textile production.

Interview with Anne PLAT

Sales Manager / Medical markets ISO 9001:2008 and ISO 13485 certification since 2013

T. +33(0)474 974 475 Cell. +33(0)623 199 285 [email protected]

Delphine GUESNON

15 A multidisciplinary R&D team of 15 engineers and technicians

Project Manager / Medical Business Development T. +33 (0)437 050 883 [email protected] www.texinov.fr

A technology with a wide range of possibilities MDB Texinov technology allows wide-ranging applications: dressing supports for complex wounds (burns, lesions, ulcers), textiles for implants used in the field of visceral surgery (hernia, eventration), urological surgery (female and male incontinence, prolapse) and orthopedic surgery (ligaments). Innovation in the genes In order to enhance its exceptional knowhow in innovation and in the design of functional technical textiles, MDB Texinov has a high-performance Research and Development team and an internal laboratory carrying out testing and quality controls on its products. Thanks to this organization, MDB Texinov is meeting very specific requirements based on standard qualities or tailored solutions. International markets The MDB Texinov team is developing its unique expertise in international markets by reinforcing its various partnerships for development at international level. Applied research and sharing of knowledge are key elements for growth. This is the reason why MDB Texinov is relying on the support of the i-Care Cluster and AEPI for its current and future projects.


7

Discover

4 Start-ups

8


CONNECTED HEALTH

At the cutting edge of research in the field of bioimpedance, BioparHom designs, produces and markets medical equipment for analysing body composition. Its fields of application are varied and equipment performance is very important in the diagnostic, clinical and scientific areas.

400

180K

5

Machines in Europe

Measurements taken

Different markets

Interview with Eva CORNET

Biomedical Engineer and President T. +33(0)951 950 818 Cell. +33(0)678 645 793 [email protected] www.bioparhom.com

ISO 9001 ISO 13485

Why was BioparHom created? Founded in 2008, BioparHom emerged from the realisation that there was a shortage of user-friendly, accurate, reliable equipment for routine clinical and sporting use. Our goal is to provide health, nutrition and sports professionals, together with researchers and vets, with measurement and diagnostic support tools that are as reliable as possible in terms of body composition data (tissues, fluid, physical condition). Constantly searching for innovations and refining the use of impedance measurement, BioparHom has managed to design and produce a range of diagnostic support systems able to measure, calculate and interpret all your physical parameters.

CE medical devices

of impedance devices that are easier to use while preserving the accuracy and expertise for which we are known. What do you hope to gain from Medica 2017? Thanks to the regional cluster and the visibility it offers, we want to take advantage of our presence at Medica to find European distributors in the nutrition and hospital sectors. Our products are innovative and powerful and satisfy a contemporary need. That’s why we and our new sales force are enthusiastic about this challenge!

What are your short-term ambitions? We primarily target the healthcare (nephrology, oncology, geriatrics etc.) and nutrition markets (medical nutrition, dieticians, nutritionists, doctors etc.). The quality of our products is now well established in these markets and we are continuing our research to improve our equipment (such as the option to use it lying down or standing up for elderly or obese patients) and, above all, provide more and more support for users. On this basis, we have raised funds to develop a new generation


9

MEDICAL DEVICES NeoMedLight is an innovative healthcare company with the unique technology of a light-emitting fabric made of woven optical fibres. The benefits of the Lightex® patented technology provide homogeneous distribution of light through optic fibers and thus a controlled light irradiance with a flexible, comfortable fabric which comforms to the patient’s anatomy. It is safe and easy to use! Its first innovation, the Bilicocoon system, targets neonatal jaundice for both premature and full-term babies. The blue light delivered by the Bilicocoon system throughout the fabric does not generate heat and is therefore safe for patients.

Interview with Sabrina LEMRAD

510(K) Cleared

Sales & Marketing Director T. +33(0)972 482 625 Cell. +33(0)669 413 454 [email protected] www.neomedlight.com

ISO 13485 certified

CE Class II

FDA approved

Founded on textile expertise NeoMedLight was born in 2014 of Brochier Technologies’ desire to fully exploit its Lightex® technology in the medical sector. Lightex® is based on a process for weaving optical fibres, making it possible to produce flexible, homogeneous luminous surfaces. In close collaboration with Dr Anne Cortey’s team (CNRHP Trousseau, Paris), NeoMedLight has identified immediate applications in phototherapy for neonatal jaundice. The BiliCocoon, a major innovation After two years of research and development, NeoMedLight presents BiliCocoon, its first phototherapy solution designed to treat neonatal jaundice. This CE-certified system consists of a flexible sleeping bag or blanket designed as a cocoon and a unit supplying the correct wavelength of light to transform and eliminate excess bilirubin. Designed for hospitals and home use, the system promotes skin-to-skin contact with the mother during treatment and enables breastfeeding without the need to interrupt the treatment. Effective and safe… discover this major innovation! One year after being granted CE approval Bilicocoon is now distributed in 16 countries (Germany, France, UK, Spain, Italy, the Nordic and Baltic countries, Thailand, Australia, Hong Kong…). Neomedlight is still looking to extend its distribution network worldwide.

10


Present in 16 countries

Distributors wanted

“The official launch of the Bilicocoon system since December 2016 has been very promising with trials conducted in different countries and positive feedback received from end users whether on the ease of use, efficacy of the device but also in terms of comfort for neonates and parent-child bonding options (cocooning, cuddling and breastfeeding)”. Sabrina LEMRAD R&D projects Neomedlight is investing resources in new therapeutic indications involving phototherapy such as treatments for mucositis and dermatitis, wound healing and tissue regeneration. The objective of NeoMedLight® is to bring the innovation to all therapeutic fields in which it will benefit patients and healthcare providers.

Strengths: • 35µW/cm2/nm - Homogenoeous and intensive irradiance • 460 nm - Effective degradation of Bilirubin by narrowband LEDs • 1200 cm2 - Large body surface area covered

CONNECTED HEALTH

Rhizom, a start-up specialising in connecting medical devices and harvesting medical data, and TAM Télésanté, a medical manufacturer and distributor specialising in midwife and birth centres, have partnered to give birth to the BBA-Évolution. This medical device is based on a smart and connected pulse-oximeter allowing for continuous monitoring of newborns.

Interview with Sylvain ZORMAN

BBA 800,000 births a year in France

ISO 13485 certified

Rhizomes from the plant world to digital… what exactly is the activity of your start-up, Rhizom? Rhizom emerged when an expert in artificial intelligence, Nicolas Pernot, got together with me, a doctor of engineering and researcher at Yale School of Medicine. We enable designers of medical devices to connect up and harvest the data collected by their equipment, just as the rhizome links and gives life to the elements that make up the network: the plant metaphor was ideal, don’t you think? To develop our concepts, we joined the incubator Innogex, where we work closely with CERN. What are your recent developments, and in which field? The market for connected objects in health is growing exponentially. Our development model is based on co-design to bring products to market quickly, drawing on the expertise of all the players involved in creating a medical device. Thanks to this model we have established a partnership with TAM Télésanté, integrating Rhizom technology with the TAM Télésanté project to create the BBA-Évolution. This product takes the form of a smart sock placed on the newborn baby’s foot, and is aimed at maternity hospitals. It is designed to preserve skin-to-skin contact in the delivery room. The slipper monitors the newborn, triggering an alarm if there are any anomalies in cardiac frequency or oxygenation.

Évolution: CE marking in progress

CEO Rhizom CE Class II

T. +33(0)754 555 504 [email protected] www.rhizom.io

Our technology collects data securely and enables it to be shared with healthcare players and patients. The field here is monitoring newborn babies, but the applications of our technology are very wide. How will the BBA-Évolution be distributed? The BBA-Évolution will be sold directly to maternity units. It will be distributed in France exclusively by NATech, the French leader in medical equipment distribution for maternity hospitals. What do you hope to gain from Medica 2017? The i-Care Cluster gives us definite visibility and strong momentum by bringing together unique skill sets. Our main objective will be to promote BBA-Evolution, but we will also aim to make contact with designers and manufacturers of medical devices who want to innovate and give their products the essential dimension of connectivity to a cloud!


11

MEDICAL DEVICES

Saint Etienne Thoracic Medical Innovation

Interview with William WIECEK

After just a few years of research and development, SETMI Médical is targeting a position as the benchmark manufacturer for the treatment of thoracic pathologies. Pneumothorax brush, vacuum bell for pectus excavatum, compression brace for pectus carinatum and prosthetic ribs… these innovative, simple-to-use, effective solutions are finding their place in the operating theatre and in our therapeutic practice. William Wiecek presents SETMI’s activities.

3

Chairman

T. +33(0)477 364 335 Cell. +33(0)643 696 247 [email protected] www.setmi-medical.com

3 families of patents registered - France, Europe, World

ISO 13485 certified by LNE/GMED

SETMI was created in response to unmet needs in thoracic surgery and pathology… Yes, our start-up emerged from needs identified by an expert thoracic surgeon, Professor Olivier Tiffet at CHU SaintÉtienne. Bringing together specialists from complementary scientific and industrial fields, Olivier Tiffet founded SETMI in 2012 and began to develop his first medical devices with his team. These were the ThoPA-Brush® (class IIA) for treating spontaneous pneumothorax and the ThoPEC® for pectus carinatum; following the necessary testing and certification, the products were brought to market in 2017. The team is currently developing further equipment, such as the T-Bell®, a vacuum bell for pectus excavatum, and the TOSCan®, a prosthetic rib.

ThoPa-Brush® and ThoPEC® brought to market in 2017

What makes your products different or innovative? Our products, and particularly the ThoPa-Brush®, are breakthrough products. The ThoPa-Brush® is a single-use device introduced using a trocar (thoracoscopy). It is used to treat pneumothorax via mechanical pleural abrasion. Surgical innovation, safety and standardisation for effective, long-lasting treatment… and real benefits in terms of patient comfort. In the same spirit, the ThoPEC® and T-Bell® approach and treat pathology differently. These treatments for sternums deformed towards the interior or exterior of the rib cage act through external aspiration or pressure. They are proven techniques and we call them compassionate products. This exhibition is a “first” for SETMI: what do you expect from it? We are currently marketing our products in France and Switzerland. This international show is a great opportunity for SETMI, because we benefit from high visibility under the banner of the Region and the i-Care Cluster. It will be a chance to form contacts and partnerships with distributors in Europe and worldwide. Our innovative solutions for thoracic surgery and pathology are easy to localise and export!

12


Contact us!

Nathalie LAURENT

[email protected]

Adriana TOMA

[email protected]

Lyon Area A Comprehensive Medtech Value Chain To attract foreign and direct investments, we are mobilizing our network of active players and experts in Health sector. A wide range of skills awaits for you: R&D, testing, manufacturing, subcontracting, distribution, regulatory consultants, clinical CROs, etc.

Single-use materials

Implantable devices & prostheses

You are interested in setting up activities in our Healthtech territory? Invest in Lyon agency provides the support you need to help you succeed.

Medical textiles

We have supported them to set up in Lyon

Electro-medical devices / dialyses

Sub-contractors

> SCIENION > COSMED

> BAXTER

> FRESENIUS

> NOVA DFL

> NEUROSOFT


13

©ESRF-AEPI

Joëlle SEUX

Adeline CICCOLELLA

Deputy Director

Head of Inward Investment, Medtechs and Life Sciences

T. +33 (0)476 709 722 Cell. +33 (0)607 799 332 [email protected] www.grenoble-isere.com

T. +33 (0)457 384 988 [email protected] www.lametro.fr

Need help to develop your business in France? We offer customized solutions: take advantage of our expertise!

200 Academic research teams

9,000

10,900

Students

Jobs

€

€

Grenoble projects rewarded at the World Competition of Innovation in 2016

Over 140 medical technology companies, 1/4 foreign-owned, employing ¾ of the sector’s workforce

The only region in France with 4 university hospitals

European Inventor Award (2016) Breakthrough Prize in Life Sciences (2015) 13 Grenoble projects rewarded at the World Competition of Innovation in 2016

• BUSINESS & SECTOR INFORMATION • SCHEDULING OF VISITS & MEETINGS • REAL ESTATE PROPOSALS & VISITS • ASSISTANCE IN OPENING & OPERATING YOUR FRENCH ORGANIZATION •RESEARCH ON FUNDING • CONNECTION WITH THE LOCAL ECOSYSTEM • HR & RECRUITING SUPPORT

Grenoble-Isère, France: Europe’s Medtech valley, where you will find sites operated by BD, Cognizant, GE, Illumina, Medtronic, Roche Diagnostics and Capgemini among others, with specific high-tech skills such as minimally invasive technologies, medical textiles, biomaterials, medical imaging, connected health, drug delivery systems, surgical navigation…

14


MEDI’NOV C O N N E C T I O N 21TH & 22TH MARCH 2018 GRENOBLE (FRANCE)

Medi’Nov Connection 2018 European meetings dedicated to the design and manufacturing of medical equipments and devices.

B2B & EXHIBITORS MEETINGS

THEMATIC TECHNOLOGY CONFERENCES

In 2017, more than 90 exhibitors (SME and start-ups) were expected to present their innovative technology and know-know to medical equipment manufacturers, through more than 3,450 B2B meetings.

ith a duration of 30 minutes W each, these conferences present technological innovations or deal with topics in relation to medical devices and equipment market evolution.

ROUND TABLES

INNOVATION PITCHES

In 2017, two sessions were organized:

ed by LyonBiopole, the Innovation L Pitches highlighted 8 innovative companies through flash presentations. At the end of the pitch session, the audience, composed of industrial companies active in the medical field, had the opportunity to vote for the most innovative company. And the winner is ... MICROLIGHT 3D.

“Standard and regulation news about medical devices”, led by the i-Care Cluster. “Growth of health technology companies: Strategy and return on operative experience”, led by MEDICALPS.

In 2017, conferences focused on 3 main themes: innovation and technology transfer, regulations and connected health.

A SHOWROOM AREA In 2017, Medi’Nov offered the opportunity to access a showroom dealing with innovative topics for the medical industry. This area allowed visitors to discover some applications related to the design and manufacturing of medical devices and equipment.

Medi’Nov Connection 2018 WTC Congress Center GRENOBLE (France)

21th & 22th March 2018

www.medinov-connection.com i-Care mag #3 / Health Technology in Auvergne-Rhône-Alpes

15

321, Avenue Jean Jaurès 69007 Lyon • France T. +33 (0)472 727 060 [email protected] HEALTH TECHNOLOGY AUVERGNE-RHÔNE-ALPES CLUSTER

@i_carecluster

www.i-carecluster.org

Saint Etienne Thoracic Medical Innovation

Auvergne - R hône - Alpes

© Michel Pérès/Région Auvergne-Rhône-Alpes & iStock photos • Design : artenium® • 10/2017 • All rights reserved

Supported by: